Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
Active, not recruiting · Phase 1, Phase 2 · NCT03793478
Conditions: Acute Myeloid Leukemia
At a glance
- Research payments reported, 2025
- $573,480
- U.S. investigators named
- 19
- Sites paid
- 20
- Planned or actual enrollment
- 65
About the trial
- Sponsor
- Daiichi Sankyo (with Innovative Therapies For Children with Cancer Consortium, Children's Oncology Group)
- Tested
- Quizartinib (drug), Fludarabine (drug), Cytarabine (drug), Intrathecal (IT) triple chemotherapy prophylaxis (drug), Etoposide (drug)
- Dates
- Started 2018-08-15; completion 2027-05-01
- Results posted
- Not yet
Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding to treatment.
From ClinicalTrials.gov, last updated 2026-04-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $573,480 in research payments for this study in 2025 (27 payments).
Products named: Vanflyta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Alok K. Kothari, MD Pediatric Hematology & Oncology · Phoenix, AZ
- Arun A. Rangaswami, MD Pediatric Hematology & Oncology · Palo Alto, CA
- Kelly Maloney, MD Pediatric Hematology & Oncology · Aurora, CO
- Jeffrey S. Dome, MD Pediatric Hematology & Oncology · Washington, DC
- Emi H. Caywood, MD Pediatric Hematology & Oncology · Wilmington, DE
- Jessica Hochberg, MD Pediatric Gastroenterology · Miami, FL
- William T. Cash, MD Pediatric Hematology & Oncology · Atlanta, GA
- Sandeep Batra, M.D. Pediatric Hematology & Oncology · Indianapolis, IN
- Kenneth Cohen, M.D. Pediatric Hematology & Oncology · Baltimore, MD
- Robin L. Williams, MD Pediatric Hematology & Oncology · Minneapolis, MN
- Amy E. Armstrong, MD Pediatric Hematology & Oncology · Saint Louis, MO
- Betty L. Herrington, MD Pediatric Hematology & Oncology · Jackson, MS
- Robin Norris, M.D., MPH Pediatric Hematology & Oncology · Cincinnati, OH
- Susan R. Rheingold, M.D. Pediatric Hematology & Oncology · Philadelphia, PA
- Jean M. Tersak, MD Specialist · Pittsburgh, PA
- Nobuko Hijiya, MD Pediatric Hematology & Oncology · Memphis, TN
- Laura J. Klesse, M.D., PH.D Pediatric Hematology & Oncology · Dallas, TX
- Douglas S. Hawkins Pediatric Hematology & Oncology · Seattle, WA
- Sarah E. Leary, M.D. Pediatric Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Public Health Institute $389,730
- Phoenix Children's Hospital, AZ $22,500
- Childrens Healthcare of Atlanta $14,750
- Children's Research Institute $14,500
- Children's Hospital Colorado, CO $12,000
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $12,000
- The University of Texas Southwestern Medical Center at Dallas $11,000
- Seattle Children's Hospital, WA $11,000
- Nemours Childrens Hospital, Florida, FL $10,000
- University of Pittsburgh $10,000
- Regents of the University of Minnesota $10,000
- Cincinnati Children's Hospital Medical Center, OH $10,000
- Johns Hopkins University $8,000
- Indiana University $7,000
- University of Mississippi Med Center, MS $7,000
- Children's Hospital of Philadelphia, PA $7,000
- Washington University $6,000
- Trustees of Columbia University in The City of New York $6,000
- New York Medical College $4,000
- University of Michigan Health System, MI $1,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.